Published in J Thromb Haemost on July 14, 2015
The antigenic complex in HIT binds to B-cells via complement and complement receptor 2 (CD21). Blood (2016) 0.76
Another surprising finding in heparin-induced thrombocytopenia--eat big. J Thromb Haemost (2015) 0.75
Heparin: Effects upon the Glycocalyx and Endothelial Cells. J Extra Corpor Technol (2017) 0.75
Macropinocytosis. Trends Cell Biol (1995) 4.03
Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood (2000) 2.78
Defining macropinocytosis. Traffic (2009) 2.56
Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials (1988) 2.32
Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med (2002) 2.23
False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost (2009) 2.14
Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med (2006) 1.77
Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood (2010) 1.76
Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol (1995) 1.76
Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J Immunol (1997) 1.75
Endocytosis unplugged: multiple ways to enter the cell. Cell Res (2010) 1.74
Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol (2008) 1.70
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood (2004) 1.63
Dynamic antibody-binding properties in the pathogenesis of HIT. Blood (2012) 1.59
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood (2005) 1.59
Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood (2014) 1.55
Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm (1998) 1.54
Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J Control Release (2001) 1.45
Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest (1994) 1.38
Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med (2001) 1.30
Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood (2000) 1.29
Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation (1997) 1.28
Determinants of PF4/heparin immunogenicity. Blood (2007) 1.25
Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood (2001) 1.23
Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol (2006) 1.21
Studies of human plate alpha-granule release in vivo. Blood (1981) 1.19
High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood (2013) 1.16
Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood (2013) 1.15
Immunogenicity of protein aggregates--concerns and realities. Int J Pharm (2012) 1.14
Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today (2011) 1.10
Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood (2008) 1.09
A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med (2008) 1.07
Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood (2010) 1.04
Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol (2010) 1.02
Heparin modifies the immunogenicity of positively charged proteins. Blood (2010) 1.00
Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood (2012) 0.99
Phagocytosis and protein processing are required for presentation of Cryptococcus neoformans mitogen to T lymphocytes. Infect Immun (2000) 0.95
Antigen stored in dendritic cells after macropinocytosis is released unprocessed from late endosomes to target B cells. Blood (2011) 0.91
Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood (2011) 0.87
Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol (2008) 0.87
Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis (2007) 0.87
B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood (2013) 0.84
Incidence of antibodies to protamine sulfate/heparin complexes incardiac surgery patients and impact on platelet activation and clinical outcome. Thromb Haemost (2013) 0.82
IL-3-mediated enhancement of particulate antigen presentation by macrophages. J Immunother (1998) 0.81
Uptake of bead-adsorbed versus soluble antigen by bone marrow derived dendritic cells triggers their activation and increases their antigen presentation capacity. Adv Exp Med Biol (1995) 0.80